AbCellera Biologics is planning to break ground in late 2021 on a manufacturing plant for therapeutic antibodies in Vancouver, British Columbia. Supported by $175.6 million in federal funding, the 130,000-sf project will cost approximately CAD$240 million to build. Offering advanced production suites, labs, offices, and warehouse space, the GMP facility will enhance the country's ability to create vaccines in response to future pandemic threats. The biomanufacturing plant is being designed by Chernoff Thompson Architects and is slated for occupancy in 2024.
AbCellera is also developing a new headquarters campus spanning an entire city block in the Mount Pleasant area of Vancouver. Comprising two buildings providing 210,000 sf and 170,00 sf, the complex will feature multidisciplinary labs for innovative research programs at the intersection of biology, machine learning, and software development. The first facility is slated for completion in 2023 with the second structure opening in 2024.